Role of platelet-activating factor in cardiovascular pathophysiology

Physiological Reviews

Volumn 80, Issue 4, 2000, Pages 1669-1699

  Montrucchio, Giuseppe ^a   Alloatti, Giuseppe ^a   Camussi, Giovanni ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; PHOSPHOLIPID; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR SYSTEM; CORONARY ARTERY BLOOD FLOW; ENDOTHELIUM CELL; HEART ATRIUM; HEART FUNCTION; HEART PAPILLARY MUSCLE; HEMODYNAMICS; HUMAN; ISOLATED HEART; LEUKOCYTE MIGRATION; LIPID METABOLISM; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SHOCK; SIGNAL TRANSDUCTION; THROMBOCYTE ADHESION; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

EID: 0033771162     PISSN: 00319333     EISSN: None     Source Type: Journal    
DOI: 10.1152/physrev.2000.80.4.1669     Document Type: Review

References (480)

1. Age-related effects of platelet activating factor (PAF) in the isolated perfused rat heart
2. Platelet-activating factor antagonism improves cardiovascular function in non-hypotensive sepsis in pigs
3. Role of platelet antagonist factor in hemorrhagic shock in pigs
4. Interference of PAF-acether antagonist BN 52021 with endotoxin-induced hypotension in the guinea pig
5. 4-like activity and on coronary flow in indomethacin-treated anaphylatic guinea-pig hearts
6. Effect of inhibition of synthesis and receptor antagonism of SRS-A in cardiac anaphylaxis
7. Choline-linked phosphoglycerides. A source of phosphatidic acid and diglycerides in stimulated neutrophils
8. Prostacyclin inhibits the platelet-dependent effects of platelet-activating factor in the rabbit isolated heart
9. Role of platelet-activating factor (PAF) in oxygen radical-induced cardiac dysfunction
10. Platelet-activating factor induced platelet/neutrophil co-operation during myocardial reperfusion
11. Effect of platelet-activating factor (PAF) on human cardiac muscle
12. Protective effect of verapamil on the cardiac and circulatory alterations induced by platelet-activating factor
13. Role of nitric oxide and platelet-activating factor in cardiac alterations induced by tumor necrosis factor-α in the guinea-pig papillary muscle
14. Activation of 1-alkyl-2-lyso-glycero-3-phosphocholine-acetyl-CoA transferase during phagocytosis in human polymorphonuclear leukocytes
15. Effects of platelet activating factor (PAF) and other vasoconstriction on a model of angiogenesis in the mouse
16. Effect of platelet activating factor (PAF) on the formation of blood vessels in subcutaneous implants in mice
17. Isolation of platelet-activating factor (PAF) from ischemic baboon myocardium
18. Cyclic blood flow variations induced by platelet-activating factor in stenosed canine coronary arteries despite inhibition of thromboxane synthetase, serotonin receptors, and adrenergic receptors
19. Inflammatory characteristics of platelet activating factor (PAF-acheter) in human skin
20. Increased PMN adherence on endothelial cells after hypoxia: Involvement of PAF, CD 18/CD 11b, and ICAM-1
21. Zymosan-induced IL-8 release from human neutrophils involves activation via the CD11b/CD18 receptor and endogenous platelet activating factor as an autocrine modulator
22. Interaction between PAF-acether and drugs that stimulate cyclic AMP in guinea-pig alveolar macrophage
23. 2
24. Platelet activating factor vasoconstriction of dog kidney: Inhibition by alprazolam
25. The role of platelet-activating factor-dependent transacetylase in the biosynthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine by stimulated endothelial cells
26. A mitogen-activated protein kinase (MAP-kinase) cascade is stimulated by platelet activating factor (PAF) in corneal epithelium
27. PAF effects on eicosanoid release in neonatal rat cardiomyocytes
28. Platelet activating factor alters receptor-coupled function in the isolated perfused rat heart
29. Platelet activating factor, a new mediator of anaphylaxis and immune complex deposition from rabbit and human basophils
30. The actions of PAF-acether (platelet-activating factor) on guinea-pig isolated heart preparations
31. Leukocyte-dependent histamine release from rabbit platelets: The role of IgE, basophils, and platelet-activating factor
32. Structural analysis of purified platelet activating factor by lipases
33. Semisynthese et structure proposee du facteur activant les plaquettes (PAF): PAF-acether un alkyl ether analogue de la lysophosphatidilcholine
34. Production and biologic interactions of prostacyclin and platelet activating factor in acute myocardial ischemia in the perfused rabbit heart
35. Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs
36. Platelet activating factor biosynthesis by cultured mesangial cells is modulated by proteinase inhibitors
37. Leukocyte adhesion in ischemia/reperfusion
38. Molecular characterization and physiological functions of PAF receptor
39. Acute microvascular effects of PAF-acether, as studied by intravital microscopy
40. 2+ channel in human and canine aortic endothelial cells
41. 2+ currents by PAF
42. Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: Higher activities in hypertensive rats
43. A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet activating lipid)
44. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine
45. The effect of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF-acether) on the arterial wall
46. Circulatory effects of PAF-acether in the newborn piglets
47. Is there a case for PAF antagonists in the treatment of ischemic states?
48. Platelet-activating factor and cellular immune response
49. Perspectives in platelet-activating factor research
50. Cellular origin of PAF
51. The mechanism of internalization of platelet activating factor in activated human neutrophils. Enhanced transbilayer movement across the plasma membrane
52. Interleukin-1 induced adhesion of polymorphonuclear leukocytes to cultured human endothelial cells. Role of platelet activating factor
53. Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism
54. Platelet activating factors alters calcium homeostasis in cultured vascular endothelial cells
55. Alpha toxin from Clostridium perfrigens induces proinflammatory changes in endothelial cells
56. The anoxic rat-heart myocyte produces and release platelet-activating factor (PAF) as a component of its ischemia-like pathology
57. Platelet-activating factor increases lung vascular permeability to protein
58. Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells
59. Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis
60. Involvement of a serine protease in the synthesis of platelet activating factor by endothelial cells stimulated by IL-1α or TNF-α
61. Interleukin-1 stimulates platelet activating factor production in human endothelial cells
62. Endothelial cells are targets for platelet activating factor. Platelet activating factor induces changes in cytoskeleton structure
63. Platelet-activating factor phosphatidate, but not platelet-activating factor, is a powerful calcium ionophore in the human red cell
64. Synthesis and release of platelet activating factor by human vascular endothelial cells treated with tumor necrosis factor and interleukin-1α
65. Production of platelet activating factor by chick retina
66. Leukocyte-endothelial cells recognition: Three (or more) steps to specificity and diversity
67. Hypotensive activity of PAF-acether in rats
68. Editorial: Interactive effects of tumor necrosis factor and platelet activating factor in the pathogenesis of glomerular injury
69. The release of platelet activating factor from human endothelial cells in culture
70. The molecular action of tumor necrosis factor-α
71. Effect of platelet activating factor on guinea-pig papillary muscle
72. Porins and lipopolysaccharides stimulate platelet activating factor synthesis by human mesangial cells
73. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet activating factor
74. Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide
75. Septic shock: The unravelling of molecular mechanisms
76. Platelet activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism
77. Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages
78. Role of soluble mediators in sepsis and renal failure
79. The role of platelet activating factor in inflammation
80. Synthesis and release of platelet-activating factor is inhibited by plasma alpha-1-proteinase inhibitor or alpha-1-antichymotrypsin and is stimulated by proteinases
81. Mediators of immune complex induced aggregation of polymorphonuclear neutrophils. II. Platelet activating factor as the effector substance of immune-induced aggregation
82. Platelet-activating factor induced loss of glomerular anionic charges
83. Mechanisms of acute vasodilator response to bacterial lipopolysaccharide in the rat coronary microcirculafion
84. Hypoxia increases stimulus-induced PAF production and release from human umbilical vein endothelial cells
85. Presence of platelet activating factor in blood from human and experimental animals. Its absence in anephric individuals
86. Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock
87. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor
88. Transendothelial neutrophil migration. Role of neutrophil-derived proteases and relationship to transendothelial protein movement
89. Aortic vascular and atrial response to 1-O-octadecyl-2-acetyl-glyceryl-3-phosphocholine
90. Effects of the PAF antagonist BN 50726 and BN 50739 on arrhythmogenesis and extent of necrosis during myocardial ischemia/reperfusion in rabbits
91. Contribution of platelets and platelet-activating factor (PAF) to the arrhythmogenic, haemodynamic and necrotic effects of acute myocardial ischemia
92. Platelet activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats
93. Beneficial effect of a platelet-activating factor, WEB 2086, on endotoxin-induced lung injury in pigs
94. Identification of receptors for platelet activating factor in rat Kupffer cells
95. Regulation of platelet activating factor receptors in rat Kupffer cells
96. Regulation of platelet activating factor receptor and PAF receptor-mediated arachidonic acid release by protein kinase C activation in rat Kupffer cells
97. Regulation of platelet activating factor receptor and platelet activating factor receptor-mediated biological responses by cAMP in rat Kupffer cells
98. Platelet activating factor-stimulated protein tyrosine phosphorylation and eicosanoid synthesis in rat Kupffer cells. Evidence for calcium-dependent and protein-kinase C-dependent and C-independent pathways
99. Protein tyrosine phosphorylation and regulation of the receptor for platelet activating factor in rat Kupffer cells. Effect of sodium vanadate
100. Platelet-activating factor: Receptor and signal transduction
101. Local vasodilator effect of platelet activating factor in the gastric, mesenteric and femoral arteries of the dog
102. 2 activation, platelet activating factor generation and prostacyclin release in spontaneously beating rat cardiomyocytes
103. Calcium influx in platelet activating factor-induced atrial natriuretic peptide release in rat cardiomyocytes
104. Biosynthesis of platelet activating factor and 1-O-acyl analogues by endothelial cells
105. Inhibition of rabbit platelet aggregation by the Ca-antagonists verapamil and diltiazem and by trifluoperazine
106. Biosynthesis of platelet-activating factor in cultured mast cells: Involvement of the CoA-independent transacylase demonstrated by analysis of the molecular species of platelet-activating factor
107. P-selectin and platelet activating factor mediate initial endotoxin-induced neutropenia
108. Experimental model of ischemic bowel necrosis: The role of platelet activating factor and endotoxin
109. Role of oxygen derived free radicals in platelet activating factor induced bowel necrosis
110. Role of platelet-activating factor-acether in mediating guinea pig anaphylaxis
111. PAF attenuates endothelium-dependent coronary arteriolar vasodilation
112. Platelet activating factor and WEB-2086 directly modulate rat cardiomyocyte contractility
113. Platelet activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators)
114. Phagocytic activation induces formation of platelet-activating factor in human monocyte-derived macrophages and in macrophage-derived foam cells. Relevance to the inflammatory reaction in atherogenesis
115. Human IL-3 stimulates endothelial cell motility and promotes in vivo new vessel formation
116. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial
117. Platelet-activating factor stimulation of tyrosine kinase and its relationship to phospholipase C in rabbit platelets: Studies with genistein and monoclonal antibody phosphotyrosine
118. PAF-achether-induced synthesis of prostacyclin by human endothelial cells
119. Effects of platelet activating factor on contractile force and Ca fluxes in guinea-pig isolated atria
120. Vasoconstriction effects of platelet-activating factor in the hamster cheek pouch microcirculation: Dose-related relations and pathways of action
121. Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist Kadsurenone
122. Presence of specific binding sites for platelet activating factor (PAF) in brain
123. Effects of coronary angioplasty on plasma platelet activating factor in man
124. PAF-acether-induced release of tissue-type plasminogen activator from vessel walls
125. The role of platelet-activating factor in conscious, normotensive endotoxemia
126. 4 immunoreactivity in the intact domestic pig heart
127. Inhibitor of platelet-activating factor diminishes dysfunction during reperfusion
128. Cardiac and coronary consequences of intracoronary platelet activating factor infusion in the domestic pig
129. Regional hemodynamic effects of antihypertensive renomedullary lipids in conscious rats
130. Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF)
131. Protective effect of BN 52021, a specific antagonist of platelet activating factor (PAF-acether) against diet-induced cholesteryl ester deposition in rabbit aorta
132. Characterization of cardiovascular events mediated by platelet activating factor during systemic anaphylaxis
133. Effect of platelet-activating factor on coronary circulation of the domestic pig
134. Effect of PAF on the cardiovascular system
135. Thyrotropin releasing hormone blocks the hypotensive effect of platelet activating factor in the unanesthetized guinea pig
136. Platelet-activating factor and cardiac diseases: Therapeutic potential for PAF inhibitors
137. Platelet activating factor and shock
138. 4 in anesthetized dogs
139. The contraction of guinea pig ileal smooth muscle by acetyl glyceryl ether phosphorylcholine
140. Platelet activating factor improves survival and attenuates eicosanoid release in severe endotoxiemia
141. Electrophysiological and arrhythmogenic effects of platelet activating factor during normal perfusion, myocardial ischemia and reperfusion in the guinea-pig
142. Angiogenic factors
143. Clinical application of research on angiogenesis
144. Reduction of infarct size by ginkgolide B (BN 52021) in coronary artery ligated rats
145. Hydrogen peroxide pretreatment of perfused canine vessels induced ICAM-1 and CD18-dependent neutrophil adherence
146. Differential signaling pathways in platelet-activating factor-induced proliferation and interleukin-6 production by rat vascular smooth muscle cells
147. Effects of PAF on cardiac function and eicosanoid release in the isolated perfused rat heart: Comparison between normotensive and spontaneously hypertensive rats
148. Effects of platelet activating factor (PAF) on blood flow distribution in the spontaneously hypertensive rat
149. Coronary and pulmonary vascular effects of leukotrienes and PAF-acether
150. Cardiovascular effects of platelet activating factor
151. Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation
152. Electrophysiological mechanisms responsible for the action of PAF in guinea-pig myocardium. Relation to the putative membrane signalling processes of PAF
153. Platelet activating factor induces tyrosine phosphorylation in human neutrophils
154. Platelet and platelet activating factor in sepsis and myocardial infarction
155. Platelet activating factor effects on bovine pulmonary artery endothelial cells
156. Effect of the PAF antagonist, BN 52021, on myocardial infarct size in dogs
157. Prevalence of increased intracellular signal transduction in immortalized lymphoblasts from patients with essential hypertension and normotensive subjects
158. Effects of ginkgo extract on two models of experimental myocardial ischemia
159. Endotoxin infusion primes elicited neutrophils and Kupffer cells for platelet-activating factor-induced and tripeptide formyl-methionine-leucine-phenylalanine-induced basal free intracellular calcium concentration responses
160. Respiratory and circulatory alterations induced by acetyl glyceryl ether phosphorylcholine, a mediator of IgE anaphylaxis in the rabbit
161. Differential effects of platelet depletion on the physiologic alteration of IgE anaphylaxis and acetyl glyceryl ether phosphorylcholine infusion in the rabbit
162. Platelet activating factor raises airway and vascular pressures and induces edema in lungs perfused with platelet-free solution
163. Platelet-activating factor: A biologically phosphoglyceride
164. Identification of platelet activating factor isolated from rabbit basophils as acetyl glyceryl ether phosphorylcholine
165. Platelet activating factor is a renal vasodilator in the anesthetized rat
166. Preclinical and clinical pharmacology of platelet activating factor receptor antagonist
167. Inhibition by SRI 63 072 and SRI 63 119 of PAF-acether and immune complex effects in the guinea pig
168. Effect of platelet activating factor on endothelial permeability to macromolecules
169. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts
170. Influence of arteriovenular pairing on PAF-induced capillary filtration
171. Cloning and expression of cDNA encoding the beta-subunit (30-kDa subunit) of bovine brain platelet-activating factor acetylhydrolase
172. cDNA cloning and expression of intracellular platelet-activating factor (PAF) acetylhydrolase II. Its omology with plasma PAF acetylhydrolase
173. Purification and characterization of bovine brain platelet-activating factor acetylhydrolase
174. Oxidatively modified LDL contains phospholipids with platelet activating factor-like activity and stimulates the growth of smooth muscle cells
175. 2
176. Human endothelial cells are target for platelet activating factor. Platelet activating factor induces platelet activating factor synthesis in human umbilical vein endothelial cells
177. Release of vasoactive amines from rabbit platelets induced by sensitized mononuclear leukocytes and antigen
178. Platelet-activating factor antagonism improves ventricular contractility in endotoxemia
179. Regulation of PAF-acether (platelet activating factor) biosynthesis in cultured human vascular endothelial cells stimulated with thrombin
180. Platelet-leukocyte interaction in adhesion to endothelial cells induced by platelet activating factor in vitro
181. PAF-mediated platelet adhesion to endothelial cells induced by FMLP-stimulated leukocytes
182. Roles of prostacyclin, EDRF and active oxygens in leukocyte-dependent platelet adhesion to endothelial cells induced by platelet activating factor in vitro
183. Thrombosis and atherosclerosis
184. Binding and internalization of platelet activating factor 1-O-alkyl-2-acetyl-glycero-3-phosphocholine in washed rabbit platelets
185. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung
186. Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver
187. Characterization of the coronary vascular responses to platelet-activating factor in the isolated perfused heart
188. Mechanisms of the coronary vascular effects of platelet-activating factor in the rat perfused heart
189. Interaction of vasoactive substances released by platelet-activating factor in the rat perfused heart
190. Neutrophil-dependent augmentation of PAF-induced vasoconstriction and albumin flux in coronary arterioles
191. Morphologic basis of increased vascular permeability induced by acetyl glyceryl ether phosphorylcholine
192. Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues
193. Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes
194. Molecular mechanisms of anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells
195. Platelet activating factor receptor is found in a large endosomal compartment in human umbilical vein endothelial cells
196. Characteristic of the binding of platelet activating factor to platelets of different animal species
197. Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor
198. Role of platelet activating-factor (PAF) on cellular responses after stimulation with leptospire lipopolysaccharide
199. Platelet activating factor and the release of platelet-derived coronary artery vasodilator substance in the canine
200. Production and release of platelet-activating factor by the injured heart-muscle cell (cardiomyocyte)
201. Hypoxia induces PECAM-1 phosphorylation and transendothelial migration of monocytes
202. Mechanisms of the hypotensive effect of 1-O-octadecyl-2-O-acetyl-glyceryl-3-phosphorylcholine
203. Distribution of PAF acetylhydrolase activity in human plasma low-density lipoprotein subfractions
204. Role of platelet activating factor in ischemia-reperfusion injury of isolated rabbit hearts: Protective effect of a specific platelet activating factor antagonist, TCV-309
205. Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs
206. Electrophysiological effects of platelet-activating factor (PAF) in guinea-pig cardiac preparations
207. Cellular electrophysiological effects of platelet-activating factor (PAF) and its antagonist BN 52021 in cardiac preparations
208. Effects of acetyl glyceryl ether phosphorylcholine (platelet activating factor) on ventricular preload, afterload and contractility in dogs
209. The potentiation of arterial contraction with platelet activating factor
210. Constriction of canine coronary arteries by platelet activating factor after brief ischemia
211. Regional haemodynamic effects of platelet activating factor in the rat
212. Myocardial reperfusion injury: Platelet activating factor stimulates polymorphonuclear leukocyte hydrogen peroxide production during myocardial reperfusion
213. Platelet activating factor antagonism attenuates platelet and neutrophil activation and reduces myocardial injury during coronary reperfusion
214. Platelet-activating factor modulates microvascular transport by stimulation of protein kinase C
215. Platelet activating factor-acetylhydrolase activity in maternal and umbilical venous plasma obtained from normotensive and hypertensive pregnancies
216. Interleukin-8 as a macrophage-derived mediator of angiogenesis
217. Cerebrovascular and cerebrometabolic effects of intracarotid infused platelet activating factor in rats
218. Platelet activating factor (PAF). A review of its effects, antagonist and possible future clinical implication (part 1)
219. Effect of BN 52021, a specific PAF-acether antagonist, on cardiac anaphylaxis in Langendorff hearts isolated from passively sensitized guinea-pigs
220. PAF antagonists as potential therapeutic agents in cardiac auaphylaxis and myocardial ischemia
221. BN 52021, a PAF receptor antagonist, protects isolated working rat heart against arrhytmias induced by ischemia but not reperfusion
222. Effect of BN 50739, a new platelet activating factor antagonist, on ischemia induced ventricular arrhythmias in isolated working rat hearts
223. Interaction of antagonist WEB 2086 and its hetrazepine analogue with human platelets and endothelial cells
224. Platelet activating factor induces NF-kB activation through a G protein-coupled pathway
225. Escherichia coli hemolysin and Staphylococcus aureus alpha-toxin potently induce neutrophil adhesion to cultured human endothelial cells
226. Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence
227. Platelet-activating factor-induced microvascular dysfunction: Role of adherent leukocytes
228. Neutrophil migration across monolayers of cytokine-prestimulated endothelial cells: A role for platelet activating factor and IL-8
229. Role of endothelial leukocyte adhesion molecule-1 and platelet activating factor in neutrophil adherence to IL-1 prestimulated endothelial cells. Endothelial leukocyte adhesion molecule-1-mediated CD18 activation
230. Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzee
231. Tumor necrosis factor alpha and interieukin 1 beta are responsive for in vitro myocardial cell depression induced by human septic shock serum
232. The human leukocyte platelet-activating factor receptor
233. Hypotensive and vasodilatatory activity of (+)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine in the normotensive rat
234. Endotoxin-induced microvascular leakage is prevented by a PAF antagonist and NO synthase inhibitor
235. 2 analog
236. Mechanisms of hypotension produced by platelet-activating factor
237. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in canine heart
238. Endotoxin releases platelet activating factor from human monocytes in vitro
239. Substrate specificity in the biocleavage of the O-alkyl-bond: 1-Alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet activating lipid) and its metabolites
240. Increased biosynthesis of platelet activating factor in activated human eosinophils
241. 1-Alkyl-2-acetyl-sn-glyceryl-3-phosphocholine (platelet activating factor) stimulates calcium influx in rabbit platelets
242. Activities of enzyme that metabolize platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in neutrophils and eosinophils from humans and the effect of a calcium ionophore
243. Formation of 1-alkyl-2-acetyl-sn-glycerols via de novo biosynthetic pathway for platelet activating factor. Characterization of 1-alkyl-2-acetyl-sn-glycero-3-phosphohydrolase in rat spleen
244. A new de novo pathway for the formation of 1-alkyl-2-acetyl-sn-glycerols, precursors of platelet activating factor. Biochemical characterization of 1-alkyl-2-lyso-sn-glycero-3-acetyl-CoA acetyltransferase in rat spleen
245. Pathophysiological mechanism of sudden death induced by platelet activating factor
246. Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet activating factor
247. The lyso-precursor of platelet-activating factor (lyso-PAF) in ischaemic myocardium
248. Effect of WEB 2086 on myocardyal infarct size and regional size and regional blood flow in the dog
249. The effects of a PAF antagonist on ischemic myocardial damage and arrhytmia in the dog
250. Ischemia aggravating effects of platelet-activating factor in acute myocardial ischemia
251. Acetyl glyceryl ether phosphorylcholine (AGEPC), a putative mediator of cardiac anaphylaxis in the guinea pig
252. Alkyl chain homologs of platelet-activating factor and their effects on the mammalian heart
253. Isolated coronary-perfused mammalian heart: Assessment of eicosanoid and platelet-activating factor release and effects
254. Calmodulin antagonist inhibits aggregation of human, guinea-pig, and rabbit platelets induced with platelet-activating factor
255. Hydrogen peroxide stimulates the synthesis of platelet activating factor by endothelium and induces endothelial cell-dependent neutrophil adhesion
256. Molecular bases of the acute coronary syndromes
257. Regulation of the surface expression of the platelet activating factor receptor in IC-21 peritoneal macrophages. Effect of lipopolysaccharide
258. Occupancy of platelet receptor for platelet activating factor in patients with septicemia
259. Inflammatory roles of P-selectin
260. Human neutrophil-derived platelet activating factor
261. Modulation of leukocyte-mediated myocardial reperfusion injury
262. Diversity in the chemical structures of neutrophil-derived platelet activating factors
263. Mechanisms of the cardioprotective actions of WEB 2170, bepafant, a platelet activating factor antagonist, in myocardial ischemia and reperfusion
264. BN 52021 protects guinea-pig from heart anaphylaxis
265. Similar coronary vascular effects in the rat perfused heart of platelet activating factor structural analogues with agonist and antagonist properties
266. Distinct platelet activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex
267. Inhibition of platelet-activating factor does not alter myocardial stunning
268. Evidence for a role of platelet activating factor in the pathogenesis of irreversible but not reversible myocardial injury after reperfusion in dogs
269. Platelet activating factor as a mediator for myocardial infarction
270. Inhibition of platelet-activating factor reduces myocardial infarct size
271. Involvement of platelet activating factor in pathologic leukocyte-endothelium interactions in the liver after hemorrhagic shock
272. Molecular and cellular actions of platelet-activating factor in rat heart cells
273. Potent hypotensive activity of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine in spontaneously hypertensive rat
274. Platelet activating factor in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome
275. Increased levels of platelet-activating factor (1-O-alkyl-2-acetylglycero-phosphocholine) in blood after reversal of renal clip hypertension in the rat
276. 4 stimulate human endothelial cells to synthesize platelet activating factor and bind neutrophils
277. 4 by human neutrophils
278. Cultured endothelial cells synthesize both platelet activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate
279. Kinetics of acetyl glyceryl ether phosphorylcholine (AGEPC)-induced acute lung alterations in the rabbit
280. Biology of disease. PAF molecular heterogeneity: Pathobiological implications
281. 1-Hexadecyl-2-acetyl-sn-glycerol stimulates differentiation of HL-60 human promyelocytic leukemia cells to macrophage-like cells
282. Biphasic effects of platelet-activating factor on coronary blood flow in anesthetized dog
283. Myocardial dysfunction and coronary vasoconstriction induced by platelet-activating factor in the post-infarcted rabbit isolated heart
284. Hypoxia induces endothelial cells to increase their adherence for neutrophils: Role of PAF
285. Effect of a cigarette smoke extract on the metabolism of the proinflammatory autacoid platelet activating factor
286. Effects of arachidonic acid metabolites and interleukin-1 on platelet activating factor production by hepatic sinusoidal endothelial cells from mice
287. Role of platelet-activating factor in polymorphonuclear neutrophil recruitment in reperfused ischemic rabbit heart
288. Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart
289. Role of platelet-activating factor in hypotension and platelet activation induced by infusion of thrombolitic agents in rabbits
290. 2 receptor antagonists but not by cyclooxygenase inhibition
291. Release of platelet-activating factor from ischemic-reperfused rabbit heart
292. In vitro contractile effect of platelet activating factor on guinea-pig myometrium
293. Streptokinase induces intravascular release of platelet activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells
294. Intravascular release of platelet-activating factor during atrial pacing
295. Tumor necrosis factor α-induced angiogenesis depends on 'in situ' platelet activating factor biosynthesis
296. Platelet-activating factor enhances VEGF-induced endothelial cell motility and neo-angiogenesis in a murine matrigel model
297. Nitric oxide mediates angiogenesis induced in vivo by platelet-activating factor and tumor necrosis factor-alpha
298. Plasmin promotes an endothelium-dependent adhesion of neutrophils. Involvement of platelet activating factor and P-Selectin
299. Involvement of nitric oxide pathway in the PAF-induced relaxation of rat thoracic aorta
300. Inflammatory actions of platelet activating factor (PAF-acether) in guinea-pig skin
301. The molecular species distribution of platelet activating factor synthesized by rabbit and human neutrophils
302. Measurement of platelet activating factor in a canine model of coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease
303. Antihypertensive lipids from the kidney: Alkyl ether analogs of phosphatidylcholine
304. Derivation of antihypertensive neutral renomedullary lipid from renal venous effluent
305. Renal medullary system of blood pressure control
306. Systemic and regional haemodynamic changes during endotoxin or platelet activating factor (PAF)-induced shock in rats
307. Polymorphonuclear leukocyte-induced vasocontraction and endothelial dysfunction. Role of selectins
308. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin
309. Platelet activating factor activates cardiac via arachidonic acid metabolites
310. Molecular cloning and expression of platelet-activating factor receptor from human leukocyte
311. Mechanism of aracludonic acid liberation in platelet activating factor-stimulated human polymorphonuclear neutrophils
312. Presence of 1-O-alk-1-enyl-2-O-acetyl-glycerophosphocholine (vinyl form of PAF) in perfused rat and guinea pig hearts
313. Species specificity of the platelet responses to 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine
314. Serum platelet activating factor acetylhydrolase during coronary artery bypass surgery
315. Common and distinct intracellular signaling pathways in human neutrophils utilized by platelet-activating factor and FMLP
316. Whole blood aggregation, thromboxane release and the lyso-derivative of platelet activating factor in myocardial infarction and unstable angina
317. Evidence the hydrolysis of ethanolamine plasmalogens triggers synthesis of platelet activating factor via a transacylase reaction
318. 2 in rat lung cytosol and differentiation from acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF-acether)
319. Biosynthesis of platelet activating factor. 1. Evidence for a acetyl-transferase activity in murine macrophages
320. Arachidonate metabolites, platelet activating factor, and the mobilization of protein kinase C in human polymorphonuclear neutrophils
321. Binding and metabolism of platelet activating factor by human neutrophils
322. 1-O-alkyl-sn-glyceryl-3-phosphorylcholine: A novel class of neutrophil stimulants
323. Administration of chronic intravenous platelet activating factor induces pulmonary arterial atrophy and hypertension in rabbits
324. Effect of TCV-309, a novel platelet activating factor antagonist, on hemodynamics in dogs with endotoxin-induced shock
325. Role of platelet-activating factor and eicosanoids during endotoxin-induced lung injury in pigs
326. Adrenergic blocking action of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine in rats
327. Hypotensive mechanism of acetyl glyceryl ether phosphorylcholine (AGEPC) in dogs. Effects of haemodynamic and humoral factors
328. Potential etiologic role of PAF in two major septic complications: Disseminated intravascular coagulation and multiple organ failure
329. Platelet activating factor stimulates transcription of the heparin-binding epidermal growth factor-like growth factor in monocytes
330. Platelet-activating factor alters glomerular barrier size selectivity for macromolecules in rats
331. 2+ concentration and contractility in isolated cardiomyocytes
332. Physicochemical and functional identity of rabbit platelet activating factor (PAF) release in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils
333. Molecular heterogeneity of platelet activating factor produced by stimulated human polymorphonuclear leukocytes
334. 4
335. Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor antagonists
336. Human endothelial cells in culture produce platelet-activating factor when stimulated with thrombin
337. Platelet-activating factor
338. Antihypertensive polar renomedullary lipids, a semi-synthetic vasodilator
339. The effects of platelet activating factor on isolated rat hearts
340. Actions of platelet-activating factor on isolated rat heart
341. Metabolism of platelet activating factor (PAF) and related ether lipids by neonatal rat myocytes
342. Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: A pilot study
343. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF-alpha) interactions in endotoxemic shock: Studies with BN 50739, a novel PAF antagonist
344. Platelet activating factor in cardiovascular stress situations
345. Endothelial-borne platelet-activating factor and interleukin-8 rapidly immobilize rolling neutrophils
346. Platelet activating factor receptor-dependent activation of the muscarinic K current in bullfrog atrial myocytes
347. Blood pressure and heart rate effects of alkyl ether phospholipids in conscious renal, spontaneously hypertensive, and normotensive rats
348. Prostaglandin F(2alpha) mediates platelet activating factor stimulated atrial natriuretic factor release from the isolated rat heart
349. Platelet-activating factor stimulates the release of atrial natriuretic factor from the rat heart
350. Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-phosphocholine (platelet activating factor and a hypotensive lipid) by cholinephosphotransferase in various rat tissues
351. The effect of PAF (platelet-activating factor) on experimental cardiac arrhythmias and its inhibition by substances influencing arachidonic acid metabolites
352. Negative inotropic effect on platelet-activating factor on human myocardium: A pharmacological study
353. Negative inotropic effect of platelet-activating factor: Association with a decrease in intracellular sodium activity
354. Activation of lysophospholipids by rabbit alveolar macrophages: Specificity of CoA-dependent, and CoA-independent reactions
355. The pathogenesis of atherosclerosis: A perspective for the 1990s
356. Platelet activating factor is a potent stimulant of the production of active oxygen species by human monocyte-derived macrophages
357. Effects of 1-O-aikyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) on cardiac function in perfused guinea-pig heart
358. Influence of BN 52021 on cardio- and hemodynamic changes during the development of postischemic shock reaction
359. Studies on the role of platelet activating factor in blood pressure regulation
360. Vascular actions of synthetic PAF acether (a synthetic platelet-activating factor) in the rat: Evidence for a platelet independent mechanism
361. Inhibition of the vascular actions of immunoglobulin G aggregates by BN 52021, a highly specific antagonist of PAF-acether
362. Platelet activating factor antagonists
363. Hemodynamic effects of platelet activating factor in the dog kidney in vivo
364. Platelet activating factor and the kidney
365. 2 synthesis in rat glomerular mesangial cells
366. Alterations in endocardial vascular resistance after reperfusion in a flow, high demand model of ischemia: Effects of dipyridamole and WEB 2086, a platelet activating factor antagonist
367. Platelet activating factor induces phospholipid turnover, calcium flux, arachidonic acid liberation, eicosanoid generation, and oncogene expression in a human B cell line
368. Platelet activating factor induced changes on renal vascular resistance, vascular reactivity, and renin release in the isolated perfused rat kidney
369. Platelet activating factor-induced homologous and heterologous desensitization in cultured vascular smooth muscle cells
370. Effects of platelet-activating factor antagonist SRI-63441 on endotoxemia in sheep
371. Elevated blood levels of platelet activating factor in patients with unstable angina
372. The binding of rabbit basophil derived platelet activating factor to rabbit platelets
373. Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcoline (platelet activating factor)
374. Platelet-activating factor receptor and signal transduction
375. Platelet-activating factor and somatostatin activate mitogen-activated protein kinase (MAP kinase) and arachidonate release
376. Platelet activating factor-induced endothelial cells expression of adhesion molecules and modulation of surface glycocalyx, evaluated by electron spectroscopy chemical analysis
377. Neutrophil interactions with endothelium and platelets: Possible role in the development of cardiovascular injury
378. Plasma mediated neutrophil stimulation during coronary angioplasty: Autocrine effect of platelet activating factor
379. Destruction of rabbit platelets in the allergic response of sensitized leukocytes. 1. Demonstration of a fluid phase intermediate
380. Effect of platelet-activating factor and its antagonist BN 52021 on cardiac function and regional blood flow in the conscious rat
381. VEGF effect on vascular permeability is mediated by synthesis of platelet-activating factor
382. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor
383. Analogs of phosphatidylcholine: Adrenergic antagonists from the renal medulla
384. Enzymatic pathways for platelet activating factor, related alkyl glycerolipids and their precursors
385. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators
386. The role of transacylase in the metabolism of arachidonate and platelet-activating factor
387. Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125(FAK)) in human endothelial cells
388. The role of PAF-acether in the mechanism of isolated coronary artery spasm under hypoxia and its inhibition by BN 52021
389. 2 in patients with septic shock and trauma
390. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
391. Human plasma platelet-activating factor acetylhydrolase: Association with lipoprotein particles in the degradation of platelet-activating factor
392. Platelet-activating factor acetylhydrolase in human tissue and blood cells
393. Beneficial effect of platelet activating factor receptor antagonist in traumatic shock
394. Salutary consequences of platelet activating factor in hemorrhagic shock
395. Detection of platelet activating factor during traumatic shock
396. Heterogeneity of vascular smooth muscle responsiveness to lipid vasoactive mediators
397. Mechanism of platelet-activating factor-induced in cardiac depression in the isolated perfused rat heart
398. PAF-acether induced cardiac dysfunction in the isolated perfused guinea pig-heart
399. Role of platelet-activating factor in propagation of cardiac damage during myocardial ischemia
400. Variation in plasma platelet activating factor degradation and serum lipids after acute myocardial infarction
401. Platelet-activating factor and the cardiovascular system: Involvement in cardiac anaphylaxis
402. Evidence that phospholipid oxidation and/or platelet activating factor play an important role in early atherogenesis. In vitro and in vivo inhibition by WEB 2086
403. Molecular cloning and characterization of the platelet activating factor receptor gene expressed in the human heart
404. Studies on the interactions of acetyl glycerol ether phosphoryl choline with the sympathetic nervous system in rats
405. Cardiac, coronary and peripheral vascular effects of acetyl glyceryl ether phosphorylcholine in the anesthetized dog
406. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide
407. Electrophysiological effects of platelet-activating factor (PAF-acether) in guinea pig-papillary muscles
408. The effect of platelet activating factor antagonist TCV-309 on arrhythmias and functional recovery during myocardial reperfusion
409. Role of platelet activating factor in pulmonary edema after coronary ligation in dogs
410. Direct effects of platelet-activating factor (PAF) on cardiac function in isolated guinea pig heart
411. Arachidonic acid release in rabbit neutrophils
412. Is platelet activating factor a mediator of endotoxic shock?
413. 1) in traumatic shock
414. Platelet activating factor contracts human myometrium in vitro
415. Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins
416. Presence of specific platelet activating factor binding sites in the rat retina
417. WEB 2086 inhibits neutrophil dependent increases in coronary resistance in blood perfused rabbit heart
418. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase
419. Lipid peroxidation in low density lipoproteins from human plasma and egg yolk promotes accumulation of 1-acyl analogues of platelet-activating factor-like lipids
420. Role of platelet activating factor in endotoxemic acute renal failure in the male rat
421. Inhibition of cyclic flow variation and reocclusion after thrombolysis in dogs by a novel antagonist of platelet activating factor
422. Effects of ONO-6240 a platelet activating factor antagonist on endotoxin shock in unanesthetized sheep
423. Metabolism of platelet-activating factor in the guinea-pig heart
424. Metabolism of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine in the human neutrophils
425. Factors that influence the proportions of platelet-activating factor and 1-acyl-2-acetyl-sn-glycero-3-phosphocholine synthesized by the mast cell
426. Biological effects of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine in the human neutrophil
427. Synthesis of 1-O-acyl-2-acetyl-sn-glycero-3-phosphocholine by an enriched preparation of the human lung mast cell
428. Differential synthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine and platelet-activating factor by human inflammatory cells
429. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme
430. Electrocardiographic alterations induced by AGEPC in Wistar rats in relation to its hypotensive and hematologic effects
431. Platelet response to the aggregatory effect of platelet activating factor (PAF) ex vivo in patients with acute myocardial infarction
432. Outer-membrane porins from gram-negative bacteria stimulate platelet activating factor biosynthesis by cultured human endothelial cells
433. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: An experimental study
434. A coenzyme A-independent transacylase is linked to the formation of platelet-activating factor (PAF) by generating the lyso-PAF intermediate in the remodeling pathway
435. Radioligand binding of antagonists of platelet activating factor to intact human platelets
436. 3H-WEB 2086
437. Conversion of alkylacetylglycerol to platelet activating factor in HL-60 cells and subcellular localization of the mediator
438. Identification of platelet activating factor receptors in P388D murine macrophages
439. Specific binding of phospholipid platelet activating factor by human platelets
440. Biphasic platelet activating factor synthesis by human monocytes stimulated with IL-1beta, tumor necrosis factor or IFN-gamma
441. Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3 phosphorylcholine
442. Platelet activating factor: Biology receptors and antagonists
443. Platelet/endothelial cell adhesion molecule-1 serves as a costimulatory agonist receptor that modulates integrin-dependent adhesion and aggregation of human platelets
444. Cardiovascular and renal action of platelet activating factor in anesthetized dogs
445. 3H-alkyl-2-arachidonoyl-sn-glycero-3-phoshocholine to lysoplatelet-activating factor by the CoA-independent transacylase in membrane fraction of human neutrophils
446. Platelet-activating factor: A phospholipid autacoid with diverse actions
447. The coronary, inotropic, chronotropic and arrhythmogenic effects of PAF-acether on isolated guinea-pig heart their selective inhibition by BN 52021
448. Effects of platelet-activating factor (PAF) and its receptor antagonist BN 52021 on isolated perfused guinea-pig heart
449. Nonimmunological production of leukotrienes induced by platelet-activating factor
450. Effects of platelet-activating factor on single potassium channel currents in guinea pig ventricular myocytes
451. Platelet activating factor mediates endotoxin-induced acute renal insufficiency in rats
452. Analysis of platelet activating factor by GC/MS after direct derivatization with penthafluorobenzoyl chloride and heptafluorobutyric anhydride
453. Fast atom bombardment-mass spectrometric identification of molecular species of platelet activating factor produced by stimulated human polymorphonuclear leukocytes
454. 1 Integrins are critically involved in neutrophil locomotion in extravascular tissue in vivo
455. Activated platelets signal chemokine synthesis by human monocytes
456. Monocytes tethering by p-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion: Signal integration and NF-kB translocation
457. Relative amounts of 1-O-alkyl- and 1-acyl-2-acetyl-sn-glycero-3-phosphocholine in stimulated endothelial cells
458. Production of platelet activating factor by endothelial cells
459. The relationship between neutrophils and increased microvascular permeability in a model of myocardial ischaemia and reperfusion in the rabbit
460. The role of CoA-independent transacylase in the production of platelet-activating factor and the metabolism of arachidonate
461. 2 activity in the human neutrophil
462. Platelet activating factor mediates cardiopulmonary dysfunction during graded bacteremic shock
463. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein
464. Enzymatic synthesis of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregation lipid
465. Dissociation of TNF-alpha from endotoxin-induced nitric oxide and acute-phase hypotension
466. Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues
467. Effect of the platelet activating factor antagonist, TCV-309, and the cyclo-oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock
468. Putative mechanism of hypotensive action of platelet activating factor in dogs
469. Stimulation of NF-kappa B activation and gene expression by platelet activating factor
470. Characterization of a human cDNA that encodes a functional receptor for platelet activating factor
471. Anoxia/reoxygenation induced neutrophil adherence to cultured endothelial cells
472. Effect of platelet activating factor on the release of arachidonic acid and prostaglandins by rabbit iris smooth muscle. Inhibition by calcium-channel antagonists
473. Protective effect of BN 50739, a new PAF antagonist, on endotoxin treated rabbits
474. Enhancement of thrombin and ionomycin-stimulated prostacyclin and platelet activating factor production in cultured endothelial cells by a tumor-promoting phorbol ester
475. Platelet activating factor stimulates transcription of the heparin-binding epidermal growth factor-like growth factor in monocytes
476. Molecular determinants of lipid mediator-induced leukocyte adherence and emigration in rat mesenteric venules
477. Endothelial cell-associated platelet activating factor: A novel mechanism for signaling intercellular adhesion
478. Production of platelet activating factor by human vascular endothelial cells: Evidence for a requirement for a specific agonist and modulation by prostacyclin
479. Platelet activating factor: A fluid-phase and cell-mediator of inflammation
480. Endothelial cell interactions with granulocytes: Tethering and signaling molecules